150.49

3.28% 4.785

Krystal Biotech Inc (KRYS)

Überblick Nachrichten Preisverlauf Optionskette Financials Warum fällt KRYS? Forum Prognose

Schlusskurs vom Vortag:

$145.70

Offen:

$146.36

24-Stunden-Volumen:

246.44K

Relative Volume:

0.68

Marktkapitalisierung:

$4.36B

Einnahmen:

$290.51M

Nettoeinkommen (Verlust:

$89.16M

KGV:

50.33

EPS:

2.99

Netto-Cashflow:

$119.18M

1W Leistung:

+0.14%

1M Leistung:

-0.93%

6M Leistung:

-19.90%

1J Leistung:

-23.81%

1-Tages-Spanne:

$145.63

$152.04

1-Wochen-Bereich:

$142.51

$152.04

52-Wochen-Spanne:

$122.80

$207.84

Krystal Biotech Inc Stock (KRYS) Company Profile

Firmenname

Krystal Biotech Inc

Sektor

Healthcare (1157)

Branche

Biotechnology (645)

Telefon

(412) 586-5830

Adresse

2100 WHARTON STREET, PITTSBURGH, PA

Mitarbeiter

275

Twitter

@KrystalBiotech

Nächster Verdiensttermin

2024-11-04

Neueste SEC-Einreichungen

KRYS's Discussions on Twitter

Vergleichen Sie KRYS mit anderen Aktien

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
KRYS Krystal Biotech Inc	150.49	4.23B	290.51M	89.16M	119.18M	2.99
VRTX Vertex Pharmaceuticals Inc	395.12	99.96B	11.39B	3.64B	3.50B	13.99
REGN Regeneron Pharmaceuticals Inc	589.48	60.83B	14.21B	4.46B	3.56B	39.68
ALNY Alnylam Pharmaceuticals Inc	454.38	59.89B	2.46B	-319.09M	-52.09M	-2.47
ARGX Argen X Se Adr	660.00	40.47B	3.06B	1.28B	447.35M	21.30
ONC Beone Medicines Ltd Adr	313.67	37.96B	3.81B	-644.79M	-669.77M	-6.24

Krystal Biotech Inc Stock (KRYS) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2025-03-05	Eingeleitet	Jefferies	Buy
2024-08-06	Herabstufung	Citigroup	Buy → Neutral
2023-11-20	Eingeleitet	Goldman	Buy
2023-10-24	Eingeleitet	Cantor Fitzgerald	Overweight
2023-10-12	Eingeleitet	Citigroup	Buy
2023-09-07	Eingeleitet	Berenberg	Buy
2023-04-18	Eingeleitet	Stifel	Buy
2023-02-28	Hochstufung	Goldman	Neutral → Buy
2022-08-25	Herabstufung	Goldman	Buy → Neutral
2022-01-18	Eingeleitet	BofA Securities	Buy
2021-07-20	Hochstufung	Goldman	Neutral → Buy
2020-09-18	Eingeleitet	B. Riley FBR	Buy
2020-06-04	Eingeleitet	Evercore ISI	Outperform
2019-09-24	Eingeleitet	Goldman	Neutral
2019-08-06	Bestätigt	H.C. Wainwright	Buy
2019-06-24	Bestätigt	Chardan Capital Markets	Buy
2019-06-24	Bestätigt	H.C. Wainwright	Buy
2019-05-30	Eingeleitet	Guggenheim	Buy
2018-09-11	Eingeleitet	Cantor Fitzgerald	Overweight

Alle ansehen

Krystal Biotech Inc Aktie (KRYS) Neueste Nachrichten

Aug 20, 2025

Krystal Biotech’s Earnings Call: Strong Growth Amid Challenges - MSN

Aug 20, 2025

Aug 19, 2025

RSI + MACD Show Convergence for Krystal Biotech Inc.July 2025 Selloffs & Daily Chart Pattern Signals - newsyoung.net

Aug 19, 2025

Aug 18, 2025

AI Trend Models Suggest Bounce for Krystal Biotech Inc.July 2025 Opening Moves & High Accuracy Investment Entry Signals - newsimpact.co.kr

Aug 18, 2025

Aug 17, 2025

Can Krystal Biotech Inc. keep up with sector leadersTrade Analysis Summary & Consistent Return Investment Signals - mustnews.co.kr

Aug 17, 2025

Aug 16, 2025

Local biotech co-founder named to Forbes 50 Over 50 - MSN

Aug 16, 2025

What are Krystal Biotech Inc.’s growth leversSwing Trade & Low Risk Investment Opportunities - thegnnews.com

Aug 16, 2025

Aug 15, 2025

Krystal Biotech Inc. Matches Institutional Buying FilterWatch List & Stock Timing and Entry Methods - newsimpact.co.kr

Aug 15, 2025

Why Krystal Biotech Inc. stock attracts strong analyst attentionMarket Movers & Technical Buy Zone Confirmations - sundaytimes.kr

Aug 15, 2025

Aug 14, 2025

Support Zone Holds Steady for Krystal Biotech Inc. After Dip2025 EndofYear Setup & Real-Time Buy Signal Notifications - beatles.ru

Aug 14, 2025

Aug 13, 2025

Evercore ISI Maintains Buy Rating on Krystal Biotech with $200 Target - AInvest

Aug 13, 2025

Aug 12, 2025

Evercore Maintains Krystal Biotech(KRYS.US) With Buy Rating, Maintains Target Price $200 - 富途牛牛

Aug 12, 2025

Aug 11, 2025

Krystal Biotech sees global VYJUVEK expansion and expects Q3 revenue dip before renewed growth - MSN

Aug 07, 2025

Aug 06, 2025

Palmoplantar Keratoderma Clinical Trials, Companies, Therapeutic Assessment, Therapies, Treatment Algorithm, Pipeline Analysis | Sol-Gel Technologies Ltd., Krystal Biotech Inc. - Barchart.com

Aug 06, 2025

Krystal Biotech Analyst Ratings: Bullish Sentiment with 6 Buy Ratings - AInvest

Aug 06, 2025

Krystal Biotech Q2 Earnings Call: Strong Growth Amid Challenges - AInvest

Aug 06, 2025

Aug 05, 2025

Krystal Biotech Shares Rise After Q2 Earnings, Revenue Beat Expectations - MSN

Aug 05, 2025

Krystal Biotech: Citigroup maintains Neutral, PT down to $166 from $176. - AInvest

Aug 05, 2025

Reassessing Krystal Biotech: Navigating Short-Term Volatility to Unlock Long-Term Value - AInvest

Aug 05, 2025

Krystal Biotech price target lowered to $182 from $192 at BofA - Yahoo Finance

Aug 05, 2025

A Quick Look at Today's Ratings for Krystal Biotech(KRYS.US), With a Forecast Between $166 to $240 - 富途牛牛

Aug 05, 2025

KRYS Q2 Earnings and Sales Top Estimates, Stock Down on Q3 Outlook - Nasdaq

Aug 05, 2025

Exploring 3 High Growth Tech Stocks In The US Market - Yahoo Finance

Aug 05, 2025

Krystal Biotech Second Quarter 2025 Earnings: Beats Expectations - uk.finance.yahoo.com

Aug 05, 2025